Huaren Pharmaceutical Co., Ltd. (SHE:300110)
China flag China · Delayed Price · Currency is CNY
2.820
-0.040 (-1.40%)
Sep 10, 2026, 3:04 PM CST

Huaren Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-471.65-462.9-1,368188.06180.78130.4
Depreciation & Amortization
107.17107.23118.36126.85149.59134.94
Other Amortization
7.49.468.578.5511.0216.45
Loss (Gain) From Sale of Assets
0.45-0.01-0.02-4.35-13.86-0.11
Asset Writedown & Restructuring Costs
528.2653187.577.036.690.28
Loss (Gain) From Sale of Investments
-0.42-2.34-0.36-0.841.390.87
Provision & Write-off of Bad Debts
9.369.369.86-48.2138.6642.19
Other Operating Activities
89.0891.521,412130.7375.7111.27
Change in Accounts Receivable
55.0251.63172.599.02135.83-1,307
Change in Inventory
27.6956.269.11-58.038.62-2.18
Change in Accounts Payable
-42.1215.81-108.13-63.84-361.01303.49
Operating Cash Flow
295.47390.23322.36305.6217.98-578.52
Operating Cash Flow Growth
-10.71%21.05%5.49%40.19%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-22.62-48.98-24.69-45.86-42.33-27.86
Sale of Property, Plant & Equipment
0.020.020.0310.0326.430.07
Cash Acquisitions
---13.67-61.61-128-431.8
Divestitures
-1.71----
Investment in Securities
000.06---
Other Investing Activities
0.360.360.360.30.091.01
Investing Cash Flow
-22.24-46.89-37.92-97.14-143.81-458.58

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-90----
Long-Term Debt Issued
-538.85843.331,4982,0101,995
Total Debt Issued
739.38628.85843.331,4982,0101,995
Short-Term Debt Repaid
--90----
Long-Term Debt Repaid
--885.7-1,130-1,606-2,179-694
Lease Payments
-0.46-0.46-0.45---
Total Debt Repaid
-976.42-975.7-1,130-1,606-2,179-694
Net Debt Issued (Repaid)
-237.04-346.86-286.24-108.26-169.121,301
Common Dividends Paid
-37.52-42.46-78.9-86.15-89.38-71.38
Other Financing Activities
-5.48-5.48-4.3773.69105.84-189.23
Financing Cash Flow
-280.03-394.8-369.5-120.72-152.671,040

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-000-0-0-0.02
Net Cash Flow
-6.81-51.45-85.0787.74-78.53.03

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
272.85341.25297.67259.74175.65-606.38
Free Cash Flow Growth
-5.86%14.64%14.60%47.87%--
Free Cash Flow Margin
20.95%25.82%22.00%15.87%10.85%-38.85%
Free Cash Flow Per Share
0.230.290.250.220.15-0.51
Levered Free Cash Flow
-70.73364.551,632293.17143.72-634.17
Unlevered Free Cash Flow
-44.5390.781,666331.61183.82-594.71
Free Cash Flow After Leases
272.39340.8297.22259.74175.65-606.38

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
124.96119.12138.89183.31146.47183.03
Change in Working Capital
25.82106.955.04-102.22-231.97-1,015